Search Results

Immunis, Inc., a private biotechnology company developing regenerative secretomes for age and disease-related immune dysfunction, is delighted to welcome Dr. Christina Weng as its newest Advisory Board member.

Immunis Inc. announces the peer-reviewed publication of research by Immunis and the University of Utah’s Professor Micah Drummond.

Immunis, Inc., a clinical-stage biotech developing innovative secretome therapies to address age-related disease and immune dysfunction, obtained a significant strategic milestone in partnering with Toray, a Japanese drug company part of the Toray Group.

Immunis Inc. is proud to unveil its latest video project entitled “Unlocking Lifelong Vitality: Immunis Aims to Supercharge Our Immune System for a Healthier Future.” This project features insights from world-renowned leaders in human health including Dr. Hans Keirstead, Jane Metcalfe, Dr. Peter Diamandis and Dr. Micah Drummond, who share a vision of revolutionizing human healthspan through the immune system.

Immunis, Inc., a private biotech creating novel cellular secretome therapies for age and disease-related immune decline, was bestowed Corporate LiveWire’s prestigious “Innovation and Excellence Award.” Corporate LiveWire is highly regarded in the business world, acknowledging the stellar performance of leading companies with technological innovation.

IMMUNIS.AI, an immunogenomics company developing blood-based cancer surveillance technologies, today announced that results from a prostate cancer risk stratification study evaluating the company’s novel blood-based liquid biopsy platform were published in The Journal of Urology.